The Technical Analyst
Bionomics Limited [BNOX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Bionomics Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.00% $0.960
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10.26 mill |
| EPS: | -2.32 |
| P/E: | -0.410 |
| Earnings Date: | Apr 22, 2024 |
| SharesOutstanding: | 10.69 mill |
| Avg Daily Volume: | 0.157 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 2/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.410 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.410 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.740 (-22.89%) $-0.220 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.868 - 1.052 ( +/- 9.58%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.960
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.960
Forecast 2: 16:00 - $0.960
Forecast 3: 16:00 - $0.960
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.960 (-2.00% ) |
| Volume | 0.0246 mill |
| Avg. Vol. | 0.157 mill |
| % of Avg. Vol | 15.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BNOX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BNOX
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Last 10 Buy Signals
Latest Press Releases
2024-03-21 06:00:00 - Press Release
Bionomics Reports Results Of The Full Dataset Analysis From Attune Phase 2b Trial Of Bnc210 In Patients With Post-traumatic Stress Disorder
Bnc210 demonstrated a statistically significant improvement in post-traumatic stress disorder (ptsd) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
2024-02-22 16:30:00 - Press Release
Bionomics To Present At The 2024 Bio Ceo & Investor Conference
Adelaide, australia and cambridge, mass., feb. 22, 2024 (globe newswire) -- bionomics limited (nasdaq: bnox) (bionomics or company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (cns) disorders with high unmet medical need, today announced that it will be presenting at the 2024 bio ceo & investor conference taking place february 26-27, 2024 in new york, ny.
2024-01-22 06:00:00 - Press Release
Bionomics Provides A Review Of 2023 And Of 2024 Plans
Positive phase 2b data announced for bnc210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (ptsd), with a discussion with the u.s. food & drug administration (fda) anticipated in q2'24.
2024-01-05 06:00:00 - Press Release
Bionomics To Present At Biotech Showcase™ 2024
The company will provide an update on its leading asset bnc210 and their partnership strategy the company will provide an update on its leading asset bnc210 and their partnership strategy
2023-12-06 08:00:00 - Press Release
Bionomics Presents Detailed Data On The Validity And Reliability Of The Subjective Units Of Distress Scale At The 2023 American College Of Neuropsychopharmacology Annual Meeting
Adelaide, australia and cambridge, mass., dec. 06, 2023 (globe newswire) -- bionomics limited (nasdaq: bnox) (bionomics or company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (cns) disorders with high unmet medical need, today announced the presentation of data on the psychometric validity and reliability of suds as an outcome measure in assessing anxiety in sad clinical trials at the 2023 american college of neuropsychopharmacology annual meeting taking place december 3 – 6 in tampa, florida.
Latest News
2024-02-22 16:30:00 - GlobeNewsWire
Bionomics to Present at the 2024 BIO CEO & Investor Conference
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.
2024-02-04 11:01:20 - InvestorPlace
7 Strong Buy Stocks Under $20: February 2024
Small-cap stocks are particularly vulnerable to higher interest rates. So it's not surprising that many of these stocks are struggling in a higher-for-longer rate environment.
2024-01-05 06:00:00 - GlobeNewsWire
Bionomics to Present at Biotech Showcase™ 2024
The Company will provide an update on its leading asset BNC210 and their partnership strategy The Company will provide an update on its leading asset BNC210 and their partnership strategy
2023-10-04 11:51:17 - PennyStocks
Penny Stocks To Buy? 3 That Insiders Are Investing $100,000+ In Now
When constructing a watch list of penny stocks, it is wise to closely monitor any legal insider trading activity. Though the rules surrounding insider trades are complex, legal filings by company executives and directors can act like signals for savvy penny stock investors.
2023-09-29 10:31:47 - Zacks Investment Research
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.
2023-09-28 10:00:06 - Proactive Investors
Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment
Shares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Researchers found that the drug, BNC210, significantly reduced the severity of PTSD symptoms over a 12-week period.The data also pointed to improvements in related issues like depression and sleep quality.
2023-09-28 08:03:38 - InvestorPlace
Why Is Bionomics (BNOX) Stock Up 347% Today?
Bionomics (NASDAQ: BNOX ) stock is rocketing higher on Thursday alongside results from a clinical trial. The clinical-stage biotechnology company revealed results from its Phase 2b ATTUNE trial of BNC210.
2023-09-28 06:13:00 - Market Watch
Bionomics announces positive results in trial of treatment for PTSD
The stock of microcap Bionomics Ltd. rose 36% early Thursday, after the company reported positive results from a mid-stage trial of a treatment for post-traumatic stress disorder.
2023-08-24 13:32:56 - Zacks Investment Research
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.
2023-06-15 08:00:00 - GlobeNewsWire
Bionomics to Present at Upcoming June Investor Conferences
ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June: